OR WAIT null SECS
Urology drugs and devices that are in the pipeline from immatics biotechnologies GmbH, Neotract Inc., Abbott Laboratories, and Beech Tree Labs, Inc.
Companies team up for phase III trial of RCC agent
Immatics biotechnologies GmbH has announced that Pfizer, Inc. has agreed to support its phase III trial of IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.
The IMPRINT (IMA901 Multi-Peptide vaccine Randomized INTernational study) trial will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with sunitinib malate (Sutent) versus sunitinib alone. The study is expected to enroll approximately 330 patients across Europe and in the U.S., according to immatics biotechnologies.
Study to test minimally invasive BPH treatment device
NeoTract Inc. recently announced that it has enrolled the first patient in a study of its UroLift System, a minimally invasive treatment approach for BPH.
The device in the system is designed to open blocked passageways that complicate urination and block the urethra by lifting prostate tissue without cutting, heating, or removing prostate tissue.
The L.I.F.T. study targets men age 50 years and older who have urinary problems related to BPH. The study is being conducted in the United States, Canada, and Australia.